MammaPrint has remained consistent and credible since introduction more than a decade ago

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

To the Editor:

One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
William Audeh
Chief medical officer, Agendia
Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
William Audeh
Chief medical officer, Agendia

Login